These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 20672371

  • 1. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, Efrati E.
    Pediatr Blood Cancer; 2010 Dec 01; 55(6):1172-9. PubMed ID: 20672371
    [Abstract] [Full Text] [Related]

  • 2. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
    Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Théoret Y, Champagne MA, Krajinovic M.
    Bone Marrow Transplant; 2010 Feb 01; 45(2):261-7. PubMed ID: 19584821
    [Abstract] [Full Text] [Related]

  • 3. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, Boelens JJ, Guchelaar HJ.
    Ther Drug Monit; 2008 Aug 01; 30(4):504-10. PubMed ID: 18641537
    [Abstract] [Full Text] [Related]

  • 4. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
    Kim I, Keam B, Lee KH, Kim JH, Oh SY, Ra EK, Yoon SS, Park SS, Kim CS, Park S, Hong YC, Kim BK.
    Clin Transplant; 2007 Aug 01; 21(2):207-13. PubMed ID: 17425746
    [Abstract] [Full Text] [Related]

  • 5. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.
    Ansari M, Rezgui MA, Théoret Y, Uppugunduri CR, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne M, Peters C, Bittencourt H, Krajinovic M, Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.
    Bone Marrow Transplant; 2013 Jul 01; 48(7):939-46. PubMed ID: 23292236
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.
    Biol Blood Marrow Transplant; 2007 Mar 01; 13(3):307-14. PubMed ID: 17317584
    [Abstract] [Full Text] [Related]

  • 7. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
    Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, Choi Y, Lim HS, Bae KS, Noh GJ, Yun SC, Han SB, Lee KH.
    Biol Blood Marrow Transplant; 2011 Aug 01; 17(8):1222-30. PubMed ID: 21215809
    [Abstract] [Full Text] [Related]

  • 8. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep 01; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 9. Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation.
    Al-Riyami I, Al-Khabori M, Al Balushi K, Al-Zadjali S, Al-Rawahi M, Dennison D, Al-Hunaini M, Al-Rawas A, Al-Moundhri M.
    Ther Drug Monit; 2022 Aug 01; 44(4):527-534. PubMed ID: 34990437
    [Abstract] [Full Text] [Related]

  • 10. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, Vassal G.
    Bone Marrow Transplant; 2003 Nov 01; 32(10):979-86. PubMed ID: 14595385
    [Abstract] [Full Text] [Related]

  • 11. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H, Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group.
    Ther Drug Monit; 2014 Feb 01; 36(1):93-9. PubMed ID: 24061446
    [Abstract] [Full Text] [Related]

  • 12. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ.
    Biol Blood Marrow Transplant; 2008 Jan 01; 14(1):88-98. PubMed ID: 18158965
    [Abstract] [Full Text] [Related]

  • 13. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
    Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T.
    Clin Chim Acta; 2006 Jun 01; 368(1-2):93-8. PubMed ID: 16448639
    [Abstract] [Full Text] [Related]

  • 14. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
    Ansari M, Huezo-Diaz P, Rezgui MA, Marktel S, Duval M, Bittencourt H, Cappelli B, Krajinovic M.
    Bone Marrow Transplant; 2016 Mar 01; 51(3):377-83. PubMed ID: 26691424
    [Abstract] [Full Text] [Related]

  • 15. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L, Leger F, Lennon S, Puozzo C.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):191-8. PubMed ID: 16133536
    [Abstract] [Full Text] [Related]

  • 16. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
    Jacobson P, Park JJ, DeFor TE, Thrall M, Abel S, Krivit W, Peters C.
    Bone Marrow Transplant; 2001 Apr 01; 27(8):855-61. PubMed ID: 11477444
    [Abstract] [Full Text] [Related]

  • 17. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT.
    ten Brink MH, Wessels JA, den Hartigh J, van der Straaten T, von dem Borne PA, Guchelaar HJ, Zwaveling J.
    Bone Marrow Transplant; 2012 Feb 01; 47(2):190-5. PubMed ID: 21441958
    [Abstract] [Full Text] [Related]

  • 18. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.
    Kim MG, Kwak A, Choi B, Ji E, Oh JM, Kim K.
    Basic Clin Pharmacol Toxicol; 2019 Jun 01; 124(6):691-703. PubMed ID: 30511436
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW.
    Biol Blood Marrow Transplant; 2004 Nov 01; 10(11):805-12. PubMed ID: 15505611
    [Abstract] [Full Text] [Related]

  • 20. Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.
    Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S.
    Ther Drug Monit; 2015 Aug 01; 37(4):493-500. PubMed ID: 25565670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.